Name	Anthony Vincent Moorman
Current Position & Affiliation	Professor of Genetic Epidemiology, Wolfson Childhood Cancer Centre, Translational and Clinical Research Institute, Newcastle University
Country	UK
Major Field	Acute Lymphoblastic Leukaemia

Educational Background

- PhD Epidemiology, Medical School, University of Leeds, 2001
- MSc Computing Science, Birkbeck College, University of London, 1996
- BSc Genetics, University of Sheffield, 1991

Professional Experience

- Reader in Genetic Epidemiology, Northern Institute for Cancer Research, Newcastle University (2008-11)
- NHS Southampton & Hampshire Local Research Ethics Committee (2003-2005)
- Senior Research Fellow, Cancer Sciences Division, University of Southampton (2001-07)
- Research Assistant, Centre for Clinical Epidemiology, University of Leeds (2001)
- PhD Student, Centre for Clinical Epidemiology, University of Leeds (1998 - 2001)
- Research Assistant, Department of Haematology, Royal Free Hospital, London (1992 - 1998)

Other Experience and Professional Memberships

University Positions (start date)

- Cancer Lead in the Precision Medicine, Genomics and Informatics Theme (2020)
- Paediatric Oncology and Leukaemia Lead with the Centre for Cancer (2019)
- REF Impact case studies working group, Faculty of Medical Sciences (2017)

National Roles/Committee Membership (start date)

- Lead for Childhood Leukaemia, Genomics England 100,000 Genomes Programme (2015)
- Lead for Biology and Research, Leukaemia Subgroup, Clinical Studies Group, National Cancer Research Institute, Children's Cancer and Leukaemia Group (2010)
- Lead for Genetics, Adult ALL Subgroup, NCRI Haematological Oncology CSG (2005)
- Blood Cancer UK Childhood Leukaemia Cell Bank Steering Committee (2004)

International Working Group Memberships (start date)

- European Working Group on Acute Lymphoblastic Leukaemia (EWALL) (2017)

- Member of the Biology and Diagnosis Committee, International Berlin-Frankfurt-Munster (BFM) clinical research study group (2005)
- Genetic Lead, Science Committee Member and Board Member in the ALLTogether consortium (2020)

Main Scientific Publications

A dedicated caller for DUX4 rearrangements from whole-genome sequencing data. Grobecker P, Berri S, Peden JF, Chow KJ, Fielding C, Armogida I, Northen H, McBride DJ, Campbell PJ, Becq J, Ryan SL, Bentley DR, Harrison CJ, **Moorman AV,** Ross MT, Mijuskovic M. BMC Med Genomics. 2025 Jan 30;18(1):24. doi: 10.1186/s12920-024-02069-1. PMID:

PAX5::AUTS2 childhood B-ALL: a relapse-prone genetic subtype with frequent central nervous system involvement and a poor outcome. Caye-Eude A, Fazio G, Pastorczak A, Boer JM, Steinemann D, Ganguli D, Sonneveld E, Haslinger S, D'Andrea L, Bradtke J, Lopes BA, Zaliova M, Escherich G, König M, Fortschegger K, Inthal A, Stasevich I, Emerenciano M, Trka J, Castillo L, Parihar M, **Moorman AV**, Bergmann AK, den Boer ML, Młynarski W, Cazzaniga G, Cavé H, Nebral K, Schinnerl D, Strehl S. Leukemia. 2025 Feb;39(2):482-486. doi: 10.1038/s41375-024-02502-5. Epub 2024 Dec 19. PMID: 39702796

Integration of genetics and MRD to define low risk patients with B-cell precursor acute lymphoblastic leukaemia with intermediate MRD levels at the end of induction. **Moorman AV**, Enshaei A, Murdy D, Joy M, Boer JM, den Boer ML, Pieters R, de Haas V, Horstmann MA, Escherich G, Johansson B, Marquart HV, Schmiegelow K, Hancock J, Moppett J, Heyman M. Leukemia. 2024 Sep;38(9):2023-2026. PMID: 38965371

ETV6::RUNX1 Acute Lymphoblastic Leukemia: how much therapy is needed for cure? Østergaard A, Fiocco M, de Groot-Kruseman H, **Moorman AV**, Vora A, Zimmermann M, Schrappe M, Biondi A, Escherich G, Stary J, Imai C, Imamura T, Heyman M, Schmiegelow K, Pieters R. Leukemia. 2024 Jul;38(7):1477-1487. PMID: 38844578

A robust and validated integrated prognostic index for defining risk groups in adult acute lymphoblastic leukemia: an EWALL collaborative study. Enshaei A, Joy M, Butler E, Kirkwood AA, Messina M, Pavoni C, Morgades M, Harrison CJ, Foà R, Ribera JM, Chiaretti S, Bassan R, Fielding AK, **Moorman AV**. Blood Adv. 2024 Mar 12;8(5):1155-1166. PMID: 38113467

Blinatumomab for First-Line Treatment of Children and Young Persons With B-ALL. Hodder A, Mishra AK, Enshaei A, Baird S, Elbeshlawi I, Bonney D, Clesham K, Cummins M, Vedi A, Gibson B, George L, Ingham D, Jigoulina G, Lancaster D, Lindsay K, Madni M, Malone A, Mitchell B, Moppett J, Motwani J, **Moorman AV**, Patrick K, Samrin L, Tewari S, Thakur I, O'Connor D, Samarasinghe S, Vora A. J Clin Oncol. 2024 Mar 10;42(8):907-914. PMID: 37967307

Real-world evaluation of UK high hyperdiploidy profile using a large cohort of patients provided by HARMONY data platform. Enshaei A, Martinez Elicegui J, Anguiano E, Gibson J, Lawal S,

Ampatzidou M, Doubek M, Fielding AK, La Sala E, Middleton E, Rijneveld AW, Turki AT, Zimmermann M, Vora A, **Moorman AV**. Leukemia. 2023 Dec;37(12):2493-2496. PMID: 37773265

Outcome for Children and Young Adults With T-Cell ALL and Induction Failure in Contemporary Trials.
Raetz EA, Rebora P, Conter V, Schrappe M, Devidas M, Escherich G, Imai C, De Moerloose B, Schmiegelow K, Burns MA, Elitzur S, Pieters R, Attarbaschi A, Yeoh A, Pui CH, Stary J, Cario G, Bodmer N, **Moorman AV**, Buldini B, Vora A, Valsecchi MG. J Clin Oncol. 2023 Nov 10;41(32):5025-5034. PMID: 37487146

Whole genome sequencing provides comprehensive genetic testing in childhood B-cell acute lymphoblastic leukaemia. Ryan SL, Peden JF, Kingsbury Z, Schwab CJ, James T, Polonen P, Mijuskovic M, Becq J, Yim R, Cranston RE, Hedges DJ, Roberts KG, Mullighan CG, Vora A, Russell LJ, Bain R, **Moorman AV**, Bentley DR, Harrison CJ, Ross MT. Leukemia. 2023 Mar;37(3):518-528. doi: 10.1038/s41375-022-01806-8. Epub 2023 Jan 19. PMID: 36658389

The genomic landscape of acute lymphoblastic leukemia with intrachromosomal amplification of chromosome 21. Gao Q, Ryan SL, Iacobucci I, Ghate PS, Cranston RE, Schwab C, Elsayed AH, Shi L, Pounds S, Lei S, Baviskar P, Pei D, Cheng C, Bashton M, Sinclair P, Bentley DR, Ross MT, Kingsbury Z, James T, Roberts KG, Devidas M, Fan Y, Chen W, Chang TC, Wu G, Carroll A, Heerema N, Valentine V, Valentine M, Yang W, Yang JJ, **Moorman AV**, Harrison CJ, Mullighan CG. Blood. 2023 Aug 24;142(8):711-723. PMID: 37216686

The Prognostic Effect of IKZF1 Deletions in ETV6::RUNX1 and High Hyperdiploid Childhood Acute Lymphoblastic Leukemia. Østergaard A, Enshaei A, Pieters R, Vora A, Horstmann MA, Escherich G, Johansson B, Heyman M, Schmiegelow K, Hoogerbrugge PM, den Boer ML, Kuiper RP, **Moorman AV**, Boer JM, van Leeuwen FN. Hemasphere. 2023 May 4;7(5):e875. PMID: 37153875

The Clinicogenomic Landscape of Induction Failure in Childhood and Young Adult T-Cell Acute Lymphoblastic Leukemia. O'Connor D, Demeulemeester J, Conde L, Kirkwood A, Fung K, Papaleonidopoulou F, Bloye G, Farah N, Rahman S, Hancock J, Bateman C, Inglott S, Mee J, Herrero J, Van Loo P, **Moorman AV**, Vora A, Mansour MR. J Clin Oncol. 2023 Jul 1;41(19):3545-3556. doi: 10.1200/JCO.22.02734. Epub 2023 Apr 25. PMID: 37098241

Leongamornlert D, Gutiérrez-Abril J, Lee S, Barretta E, Creasey T, Gundem G, Levine MF, Arango-Ossa JE, Liosis K, Medina-Martinez JS, Zuborne Alapi K, Kirkwood AA, Clifton-Hadley L, Patrick P, Jones D, O'Neill L, Butler AP, Harrison CJ, Campbell P, Patel B, **Moorman AV**, Fielding AK, Papaemmanuil E. Diagnostic utility of whole genome sequencing in adults with B-other acute lymphoblastic leukemia. Blood Adv. 2023 Aug 8;7(15):3862-3873. doi: 10.1182/bloodadvances.2022008992. PMID: 36867579

Schwab C, Cranston RE, Ryan SL, Butler E, Winterman E, Hawking Z, Bashton M, Enshaei A, Russell LJ, Kingsbury Z, Peden JF, Barretta E, Murray J, Gibson J, Hinchliffe AC, Bain R, Vora A, Bentley DR, Ross MT, **Moorman AV**, Harrison CJ. Integrative genomic analysis of childhood

acute lymphoblastic leukaemia lacking a genetic biomarker in the UKALL2003 clinical trial. Leukemia. 2023 Mar;37(3):529-538. doi: 10.1038/s41375-022-01799-4. Epub 2022 Dec 22. PMID: 36550215

Moorman AV, Antony G, Wade R, Butler ER, Enshaei A, Harrison CJ, Moppett J, Hough R, Rowntree C, Hancock J, Goulden N, Samarasinghe S, Vora A. Time to Cure for Childhood and Young Adult Acute Lymphoblastic Leukemia Is Independent of Early Risk Factors: Long-Term Follow-Up of the UKALL2003 Trial. J Clin Oncol. 2022 Dec 20;40(36):4228-4239. doi: 10.1200/JCO.22.00245. Epub 2022 Jun 17. PMID: 35714315

Bomken S, Enshaei A, Schwalbe EC, Mikulasova A, Dai Y, Zaka M, Fung KT, Bashton M, Lim H, Jones L, Karataraki N, Winterman E, Ashby C, Attarbaschi A, Bertrand Y, Bradtke J, Buldini B, Burke GA, Cazzaniga G, Gohring G, De Groot-Kruseman HA, Haferlach C, Nigro LL, Parihar M, Plesa A, Seaford E, Sonneveld E, Strehl S, Van der Velden VH, Rand V, Hunger SP, Harrison CJ, Bacon CM, Van Delft FW, Loh ML, Moppett J, Vormoor J, Walker BA, **Moorman AV**, Russell LJ. Molecular characterisation and clinical outcome of B-cell precursor acute lymphoblastic leukaemia with IG-MYC rearrangement. Haematologica. 2023 Mar 1;108(3):717-731. doi: 10.3324/haematol.2021.280557. PMID: 35484682

Marks DI, Clifton-Hadley L, Copland M, Hussain J, Menne TF, McMillan A, **Moorman AV**, Morley N, Okasha D, Patel B, Patrick P, Potter MN, Rowntree CJ, Kirkwood AA, Fielding AK. In-vivo T-cell depleted reduced-intensity conditioned allogeneic haematopoietic stem-cell transplantation for patients with acute lymphoblastic leukaemia in first remission: results from the prospective, single-arm evaluation of the UKALL14 trial.
Lancet Haematol. 2022 Apr;9(4):e276-e288. doi: 10.1016/S2352-3026(22)00036-9. PMID: 35358442

Marks DI, Kirkwood AA, Rowntree CJ, Aguiar M, Bailey KE, Beaton B, Cahalin P, Castleton AZ, Clifton-Hadley L, Copland M, Goldstone AH, Kelly R, Lawrie E, Lee S, McMillan AK, McMullin MF, Menne TF, Mitchell RJ, **Moorman AV**, Patel B, Patrick P, Smith P, Taussig D, Yallop D, Alapi KZ, Fielding AK. Addition of four doses of rituximab to standard induction chemotherapy in adult patients with precursor B-cell acute lymphoblastic leukaemia (UKALL14): a phase 3, multicentre, randomised controlled trial. Lancet Haematol. 2022 Apr;9(4):e262-e275. doi: 10.1016/S2352-3026(22)00038-2. PMID: 35358441

Sidhu J, Masurekar AN, Gogoi MP, Fong C, Ioannou T, Lodhi T, Parker C, Liu J, Kirkwood AA, **Moorman AV**, Das K, Goulden NJ, Vora A, Saha V, Krishnan S. Activity and toxicity of intramuscular 1000 iu/m2 polyethylene glycol-E. coli L-asparaginase in the UKALL 2003 and UKALL 2011 clinical trials. Br J Haematol. 2022 Jul;198(1):142-150. doi: 10.1111/bjh.18158. Epub 2022 Mar 29

Creasey T, Barretta E, Ryan SL, Butler E, Kirkwood AA, Leongamornlert D, Papaemmanuil E, Patrick P, Clifton-Hadley L, Patel B, Menne T, McMillan AK, Harrison CJ, Rowntree CJ, Morley N, Marks DI, Fielding AK, **Moorman AV**. Genetic and genomic analysis of acute lymphoblastic leukaemia in older adults reveals a distinct profile of abnormalities: analysis of 210 patients from the UKALL14 and UKALL60+ clinical trials.

Haematologica. 2021 Nov 18. doi: 10.3324/haematol.2021.279177.

Enshaei A, Vora A, Harrison CJ, Moppett J, **Moorman AV**. Defining low-risk high hyperdiploidy in patients with paediatric acute lymphoblastic leukaemia: a retrospective analysis of data from the UKALL97/99 and UKALL2003 clinical trials. Lancet Haematol. 2021 Nov;8(11):e828-e839. doi: 10.1016/S2352-3026(21)00304-5.

Schwab CJ, Murdy D, Butler E, Enshaei A, Winterman E, Cranston RE, Ryan S, Barretta E, Hawking Z, Murray J, Antony G, Vora A, **Moorman AV**, Harrison CJ. Genetic characterisation of childhood B-other-acute lymphoblastic leukaemia in UK patients by fluorescence in situ hybridisation and Multiplex Ligation-dependent Probe Amplification. Br J Haematol. 2021 Oct 21. doi: 10.1111/bjh.17869.

Moorman AV, Barretta E, Butler ER, Ward EJ, Twentyman K, Kirkwood AA, Enshaei A, Schwab C, Creasey T, Leongamornlert D, Papaemmanuil E, Patrick P, Clifton-Hadley L, Patel B, Menne T, McMillan AK, Harrison CJ, Rowntree CJ, Marks DI, Fielding AK. Prognostic impact of chromosomal abnormalities and copy number alterations in adult B-cell precursor acute lymphoblastic leukaemia: a UKALL14 study. Leukemia. 2021 Oct 16. doi: 10.1038/s41375-021-01448-2.

Eckert C, Parker C, **Moorman AV**, Irving JA, Kirschner-Schwabe R, Groeneveld-Krentz S, Révész T, Hoogerbrugge P, Hancock J, Sutton R, Henze G, Chen-Santel C, Attarbaschi A, Bourquin JP, Sramkova L, Zimmermann M, Krishnan S, von Stackelberg A, Saha V. Risk factors and outcomes in children with high-risk B-cell precursor and T-cell relapsed acute lymphoblastic leukaemia: combined analysis of ALLR3 and ALL-REZ BFM 2002 clinical trials. Eur J Cancer. 2021 Jul;151:175-189

Creasey T, Enshaei A, Nebral K, Schwab C, Watts K, Cuthbert G, Vora A, Moppett J, Harrison CJ, Fielding AK, Haas OA, **Moorman AV**. Single nucleotide polymorphism array-based signature of low hypodiploidy in acute lymphoblastic leukemia. Genes Chromosomes Cancer. 2021 May 3. doi: 10.1002/gcc.22956. Online ahead of print.

den Boer ML, Cario G, **Moorman AV**, Boer JM, de Groot-Kruseman HA, Fiocco M, Escherich G, Imamura T, Yeoh A, Sutton R, Dalla-Pozza L, Kiyokawa N, Schrappe M, Roberts KG, Mullighan CG, Hunger SP, Vora A, Attarbaschi A, Zaliova M, Elitzur S, Cazzaniga G, Biondi A, Loh ML, Pieters R; Ponte di Legno Childhood ALL Working Group. Outcomes of paediatric patients with B-cell acute lymphocytic leukaemia with ABL-class fusion in the pre-tyrosine-kinase inhibitor era: a multicentre, retrospective, cohort study. Lancet Haematol. 2021 Jan;8(1):e55-e66.

Moorman AV, Schwab C, Winterman E, Hancock J, Castleton A, Cummins M, Gibson B, Goulden N, Kearns P, James B, Kirkwood AA, Lancaster D, Madi M, McMillan A, Motwani J, Norton A, O'Marcaigh A, Patrick K, Bhatnagar N, Qureshi A, Richardson D, Stokley S, Taylor G, van Delft FW, Moppett J, Harrison CJ, Samarasinghe S, Vora A. Adjuvant tyrosine kinase inhibitor therapy improves outcome for children and adolescents with acute lymphoblastic leukaemia who have an ABL-class fusion. Br J Haematol. 2020 Dec;191(5):844-851

Enshaei A, O'Connor D, Bartram J, Hancock J, Harrison CJ, Hough R, Samarasinghe S, den Boer ML, Boer JM, de Groot-Kruseman HA, Marquart HV, Noren-Nystrom U, Schmiegelow K, Schwab C, Horstmann MA, Escherich G, Heyman M, Pieters R, Vora A, Moppett J, **Moorman AV**. A validated novel continuous prognostic index to deliver stratified medicine in pediatric acute lymphoblastic leukemia. Blood (2020) 135 (17): 1438–1446.

Hamadeh L, Enshaei A, Schwab C, Alonso CN, Attarbaschi A, Barbany G, den Boer ML, Boer JM, Braun M, Dalla Pozza L, Elitzur S, Emerenciano M, Fechina L, Felice MS, Fronkova E, Haltrich I, Heyman MM, Horibe K, Imamura T, Jeison M, Kovács G, Kuiper RP, Mlynarski W, Nebral K, Ivanov Öfverholm I, Pastorczak A, Pieters R, Piko H, Pombo-de-Oliveira MS, Rubio P, Strehl S, Stary J, Sutton R, Trka J, Tsaur G, Venn N, Vora A, Yano M, Harrison CJ, **Moorman AV**. Validation of the United Kingdom copy-number alteration classifier in 3239 children with B-cell precursor ALL. Blood Adv. 2019 Jan 22;3(2):148-157.

O'Connor D, Enshaei A, Bartram J, Hancock J, Harrison CJ, Hough R, Samarasinghe S, Schwab C, Vora A, Wade R, Moppett J, **Moorman AV***, Goulden N. Genotype-Specific Minimal Residual Disease Interpretation Improves Stratification in Pediatric Acute Lymphoblastic Leukemia. J Clin Oncol. 2018 Jan 1;36(1):34-43. * Joint last author and corresponding author

O'Connor D*, **Moorman AV***, Wade R, Hancock J, Tan RM, Bartram J, Moppett J, Schwab C, Patrick K, Harrison CJ, Hough R, Goulden N, Vora A, Samarasinghe S. Use of Minimal Residual Disease Assessment to Redefine Induction Failure in Pediatric Acute Lymphoblastic Leukemia. J Clin Oncol. 2017;35(6):660-667. * Joint first author